FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159540282> ?p ?o ?g. }

• W3159540282 endingPage "538" @default.
• W3159540282 startingPage "529" @default.
• W3159540282 abstract "Abstract Aim The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) showed that tafamidis reduced all-cause mortality and cardiovascular-related hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). This study aimed to estimate the impact of tafamidis on survival and quality-adjusted life-years (QALYs). Methods and results A multi-state, cohort, Markov model was developed to simulate the disease course of ATTR-CM throughout a lifetime. For survival extrapolation, survival curves were fitted by treatment arm and New York Heart Association (NYHA) Class I/II (68% of patients) and NYHA Class III (32% of patients) cohorts using the individual patient-level data from both the ATTR-ACT and the corresponding long-term extension study. Univariate and multivariate sensitivity analyses were conducted. The predicted mean survival for the total population (NYHA Class I/II + III) was 6.73 years for tafamidis and 2.85 years for the standard of care (SoC), resulting in an incremental mean survival of 3.88 years [95% confidence interval (CI) 1.32–5.66]. Of the 6.73 life-years, patients on tafamidis spend, on average, 4.82 years in NYHA Class I/II, while patients on SoC spend an average of 1.60 life-years in these classes. The combination of longer survival in lower NYHA classes produced a QALY gain of 5.39 for tafamidis and 2.11 for SoC, resulting in 3.29 incremental QALYs (95% CI 1.21–4.74) in favour of tafamidis. Conclusion Based on the disease simulation model results, tafamidis is expected to more than double the life expectancy and QALYs of ATTR-CM patients compared to SoC. Longer-term follow-up data from the ATTR-ACT extension study will further inform these findings. Clinical trials.gov identifier NCT01994889 (date of registration: 26 November 2013)." @default.
• W3159540282 created "2021-05-10" @default.
• W3159540282 creator A5001887894 @default.
• W3159540282 creator A5023195809 @default.
• W3159540282 creator A5029389400 @default.
• W3159540282 creator A5035040485 @default.
• W3159540282 creator A5039926945 @default.
• W3159540282 creator A5065594480 @default.
• W3159540282 creator A5066994600 @default.
• W3159540282 creator A5080737514 @default.
• W3159540282 creator A5083256847 @default.
• W3159540282 creator A5088524760 @default.
• W3159540282 date "2021-04-24" @default.
• W3159540282 modified "2023-10-16" @default.
• W3159540282 title "Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies" @default.
• W3159540282 cites W123436534 @default.
• W3159540282 cites W139699688 @default.
• W3159540282 cites W1973380773 @default.
• W3159540282 cites W1995945562 @default.
• W3159540282 cites W2009082034 @default.
• W3159540282 cites W2011246655 @default.
• W3159540282 cites W2023924430 @default.
• W3159540282 cites W2039405418 @default.
• W3159540282 cites W2076003266 @default.
• W3159540282 cites W2081195053 @default.
• W3159540282 cites W2081338080 @default.
• W3159540282 cites W2096782143 @default.
• W3159540282 cites W2113117011 @default.
• W3159540282 cites W2123394243 @default.
• W3159540282 cites W2158196600 @default.
• W3159540282 cites W2254731646 @default.
• W3159540282 cites W2377410957 @default.
• W3159540282 cites W2465483060 @default.
• W3159540282 cites W2509971241 @default.
• W3159540282 cites W2599639624 @default.
• W3159540282 cites W2626332910 @default.
• W3159540282 cites W2743793531 @default.
• W3159540282 cites W2754319823 @default.
• W3159540282 cites W2796659008 @default.
• W3159540282 cites W2887352853 @default.
• W3159540282 cites W2888036721 @default.
• W3159540282 cites W2907261593 @default.
• W3159540282 cites W2944922806 @default.
• W3159540282 cites W2964208467 @default.
• W3159540282 cites W2971824914 @default.
• W3159540282 cites W2981337130 @default.
• W3159540282 cites W3001354239 @default.
• W3159540282 cites W3006028248 @default.
• W3159540282 cites W3011104356 @default.
• W3159540282 cites W3023844952 @default.
• W3159540282 cites W3093386527 @default.
• W3159540282 cites W620632278 @default.
• W3159540282 doi "https://doi.org/10.1093/ehjqcco/qcab031" @default.
• W3159540282 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33895806" @default.
• W3159540282 hasPublicationYear "2021" @default.
• W3159540282 type Work @default.
• W3159540282 sameAs 3159540282 @default.
• W3159540282 citedByCount "8" @default.
• W3159540282 countsByYear W31595402822021 @default.
• W3159540282 countsByYear W31595402822023 @default.
• W3159540282 crossrefType "journal-article" @default.
• W3159540282 hasAuthorship W3159540282A5001887894 @default.
• W3159540282 hasAuthorship W3159540282A5023195809 @default.
• W3159540282 hasAuthorship W3159540282A5029389400 @default.
• W3159540282 hasAuthorship W3159540282A5035040485 @default.
• W3159540282 hasAuthorship W3159540282A5039926945 @default.
• W3159540282 hasAuthorship W3159540282A5065594480 @default.
• W3159540282 hasAuthorship W3159540282A5066994600 @default.
• W3159540282 hasAuthorship W3159540282A5080737514 @default.
• W3159540282 hasAuthorship W3159540282A5083256847 @default.
• W3159540282 hasAuthorship W3159540282A5088524760 @default.
• W3159540282 hasBestOaLocation W31595402821 @default.
• W3159540282 hasConcept C121157162 @default.
• W3159540282 hasConcept C126322002 @default.
• W3159540282 hasConcept C143998085 @default.
• W3159540282 hasConcept C2778198053 @default.
• W3159540282 hasConcept C2778797674 @default.
• W3159540282 hasConcept C44249647 @default.
• W3159540282 hasConcept C71924100 @default.
• W3159540282 hasConcept C72563966 @default.
• W3159540282 hasConceptScore W3159540282C121157162 @default.
• W3159540282 hasConceptScore W3159540282C126322002 @default.
• W3159540282 hasConceptScore W3159540282C143998085 @default.
• W3159540282 hasConceptScore W3159540282C2778198053 @default.
• W3159540282 hasConceptScore W3159540282C2778797674 @default.
• W3159540282 hasConceptScore W3159540282C44249647 @default.
• W3159540282 hasConceptScore W3159540282C71924100 @default.
• W3159540282 hasConceptScore W3159540282C72563966 @default.
• W3159540282 hasFunder F4320307765 @default.
• W3159540282 hasIssue "5" @default.
• W3159540282 hasLocation W31595402821 @default.
• W3159540282 hasLocation W31595402822 @default.
• W3159540282 hasLocation W31595402823 @default.
• W3159540282 hasLocation W31595402824 @default.
• W3159540282 hasLocation W31595402825 @default.
• W3159540282 hasOpenAccess W3159540282 @default.
• W3159540282 hasPrimaryLocation W31595402821 @default.
• W3159540282 hasRelatedWork W1598177992 @default.

• next